Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Jill Slansky to Receptors, Antigen, T-Cell

This is a "connection" page, showing publications Jill Slansky has written about Receptors, Antigen, T-Cell.

 
Connection Strength
 
 
 
2.737
 
  1. Hoffmann MM, Slansky JE. T-cell receptor affinity in the age of cancer immunotherapy. Mol Carcinog. 2020 07; 59(7):862-870.
    View in: PubMed
    Score: 0.536
  2. Munson DJ, Egelston CA, Chiotti KE, Parra ZE, Bruno TC, Moore BL, Nakano TA, Simons DL, Jimenez G, Yim JH, Rozanov DV, Falta MT, Fontenot AP, Reynolds PR, Leach SM, Borges VF, Kappler JW, Spellman PT, Lee PP, Slansky JE. Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A. 2016 07 19; 113(29):8272-7.
    View in: PubMed
    Score: 0.409
  3. Buhrman JD, Jordan KR, Munson DJ, Moore BL, Kappler JW, Slansky JE. Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem. 2013 Nov 15; 288(46):33213-25.
    View in: PubMed
    Score: 0.340
  4. Slansky JE, Jordan KR. The Goldilocks model for TCR-too much attraction might not be best for vaccine design. PLoS Biol. 2010 Sep 14; 8(9).
    View in: PubMed
    Score: 0.274
  5. McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson DB, Slansky JE. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest. 2006 Sep; 116(9):2543-51.
    View in: PubMed
    Score: 0.207
  6. Slansky JE. Antigen-specific T cells: analyses of the needles in the haystack. PLoS Biol. 2003 Dec; 1(3):E78.
    View in: PubMed
    Score: 0.172
  7. Hay ZLZ, Knapp JR, Magallon RE, O'Connor BP, Slansky JE. Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2023 05 03; 11(5):570-582.
    View in: PubMed
    Score: 0.165
  8. Wang Y, Tsitsiklis A, Devoe S, Gao W, Chu HH, Zhang Y, Li W, Wong WK, Deane CM, Neau D, Slansky JE, Thomas PG, Robey EA, Dai S. Peptide Centric V? Specific Germline Contacts Shape a Specialist T Cell Response. Front Immunol. 2022; 13:847092.
    View in: PubMed
    Score: 0.156
  9. Wei P, Jordan KR, Buhrman JD, Lei J, Deng H, Marrack P, Dai S, Kappler JW, Slansky JE, Yin L. Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer. Proc Natl Acad Sci U S A. 2021 06 08; 118(23).
    View in: PubMed
    Score: 0.144
  10. Slansky JE, Nakayama M. Peptide mimotopes alter T cell function in cancer and autoimmunity. Semin Immunol. 2020 02; 47:101395.
    View in: PubMed
    Score: 0.133
  11. Jordan KR, Buhrman JD, Sprague J, Moore BL, Gao D, Kappler JW, Slansky JE. TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother. 2012 Oct; 61(10):1627-38.
    View in: PubMed
    Score: 0.076
  12. Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A. 2010 Mar 09; 107(10):4652-7.
    View in: PubMed
    Score: 0.066
  13. Crawford F, Jordan KR, Stadinski B, Wang Y, Huseby E, Marrack P, Slansky JE, Kappler JW. Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands. Immunol Rev. 2006 Apr; 210:156-70.
    View in: PubMed
    Score: 0.050
  14. Schneck JP, Slansky JE, O'Herrin SM, Greten TF. Monitoring antigen-specific T cells using MHC-Ig dimers. Curr Protoc Immunol. 2001 May; Chapter 17:Unit 17.2.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)